I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Molecular basis of PD-1 blockade by dostarlimab, the FDA-ap..:
Park, Ui Beom
;
Jeong, Tae Jun
;
Gu, Nahyeon
..
Biochemical and Biophysical Research Communications. 599 (2022) - p. 31-37 , 2022
Link:
https://doi.org/10.1016/j.bbrc.2022.02.026
RT Journal T1
Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy
UL https://suche.suub.uni-bremen.de/peid=cr-10.1016_j.bbrc.2022.02.026&Exemplar=1&LAN=DE A1 Park, Ui Beom A1 Jeong, Tae Jun A1 Gu, Nahyeon A1 Lee, Hyun Tae A1 Heo, Yong-Seok PB Elsevier BV YR 2022 SN 0006-291X JF Biochemical and Biophysical Research Communications VO 599 SP 31 OP 37 LK http://dx.doi.org/https://doi.org/10.1016/j.bbrc.2022.02.026 DO https://doi.org/10.1016/j.bbrc.2022.02.026 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)